BioCentury
ARTICLE | Company News

Quest Pharma, Shenzhen Hepalink Pharmaceutical deal

April 4, 2016 7:00 AM UTC

Quest’s OncoQuest Inc. subsidiary and Hepalink formed newco OncoVent Co. Ltd. to develop immunotherapies for cancer in China. Hepalink will own 54% of OncoVent’s shares, and Quest PharmaTech and Onco...